PARP Inhibitors: A Breakthrough in Cancer Chemotherapy

Mohd Imran Ansari, Chad Johnson and Andrew Coop*

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, USA

*Corresponding author: Andrew Coop, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, USA

Submission: April 04, 2018; Published: May 15, 2018

Abstract

Among the 17 members of Poly (ADP-ribose) polymerase enzyme family, PARP-1 is a very crucial DNA repair enzyme and the level of PARP-1 is found elevated in several cancers such as ovarian, triple negative breast cancer. Inhibitors of PARP-1 is a new feature of anticancer drug development. In this mini, we covered the mode of action, recent development and approval of PARP-1 inhibitors. We also provide an insight on designing strategy of novel PARP-1 inhibitors and future direction.

Keywords: PARP inhibitors; Poly ADP ribose polymenase (PARP) family; Single strand break repair; Breast Cancer; Ovarian Cancer; DNA lipase


Introduction

Among the 17 family members of poly ADP ribose polymerase (PARP) family, PARP-1 is comprehensively studied because of its critical roles in cancer [1]. The PARP family of proteins have been shown to regulate a vast number of cellular processes including DNA repair, stability of the genome (i.e. mammalian longevity), and programmed cell death.

The DNA repair function of PARP involves it’s assisting in the repair of single strand DNA "nicks" or breaks. The single strand break repair (SSBR) mechanism is activated when DNA damage occurs via exposure to DNA damaging agents both exogenous and endogenous (e.g. radiation exposure, chemotherapeutic agents). When PARP detects DNA damage it will bind to the damaged strand via N-terminal zinc fingers and undergoes a structural change. The synthesis of the polymeric adenosine diphosphate ribose (poly (ADP-ribose) or PAR) chain triggers the recruitment of other endogenous DNA repair enzymes [2]. However, DNA damage machinery, if deregulated, can lead to genetic mutations, which facilitate cancer development [3]. As certain cancer cell lines have been found to be defective in homologous recombination mechanisms, they may rely on PARP-mediated SSBR for survival. Therefore, inhibitors of PARP will prevent cancer cells from efficiently repairing their DNA, and increase their sensitivity to chemotherapeutics. For the last 3 decades, several PARP-1 inhibitors have been evaluated for their therapeutic potentials and later employed in clinical settings to treat cancer (e.g. breast cancer, ovarian cancer) [4].

PARP-1 was the first protein in the family identified and remains the best characterized. PARP-2 is most closely related to PARP-1, with 69% similarity in their catalytic domains. It was identified in PARP-1 deficient cells that still showed PARP activity [5]. While PARP-2 functions in a similar manner to PARP-1, it is much less abundant, contributing only 5-10% of total PARP activity [6]. It has been shown that PARP-1/PARP-2 oligomerizes when assisting in the repair of SSBR’s therefore PARP-1 inhibitors also inhibit PARP-2 [2]. PARP-1 inhibitors, in combination with anticancer agents such as DNA damaging chemotherapeutics have improved their efficiency [4]. PARP-1 inhibitors are also useful as stand-alone therapeutics in cancer types that have impaired DNA repair activities (e.g. breast cancer type 1/2 susceptibility protein (BRCA-1/2) mutations.

Mode of action

The PARP proteins are a family of stress response proteins approximately 116kDa that catalyze the transfer of ADP ribose to target proteins. Each of the 18 proteins is encoded by different genes, but all share a conserved catalytic domain. PARP is composed of four primary domains: the DNA binding domain, a caspase-cleaved domain, and auto-modification domain, and a catalytic domain. While it is appreciated that the PARP family is likely involved in several cellular processes including cell proliferation and death, the PARP family has gained notoriety for their involvement in DNA repair processes. Evidence for PARP-mediated DNA repair
comes from the observation that the DNA damaging agents (e.g. chemotherapy and radiation) caused increased PARP activity [7].

PARP-1 and 2 are both activated by DNA SSBR's. The DNA binding domain contains two zinc finger motifs which bind the damaged DNA and cause a conformational change bringing the N and C termini closer proximity. This action triggers the C-terminal catalytic domain (CAT) that hydrolyzes NAD+ to produce both linear and branched polymeric adenosine diphosphate ribose (PAR) polymers. This post-translational modification is known as PARylation, and it signals DNA ligase III, DNA polymerase beta, and other scaffolding proteins such as X-ray cross-complementing gene for DNA repair [8]. The PAR chain is subsequently degraded via poly (ADP-ribose) glycohydrolase (PARG) [9]. The oligomerization of PARP-1/2 has also been shown to stimulate PARP catalytic activity. This chain can extend up to 200 nucleotides before inducing any apoptotic processes via stimulation of the mitochondria to release apoptosis inducing factor (APF). Since NAD+ is required to generate these ADP-ribose monomers it has been thought that the synthesis of these chains depletes the cellular stores of NAD+. This is followed by progressive ATP depletion, which in turn induces necrotic cell death due to inhibition of glucose oxidation. More recently Andrabi [10] showed that inhibition of hexokinase inhibits this activity [9]. PARP is inactivated by caspase-3 cleavage which proteolytically cleaves PARP into 89kDA and 24kDA fragments-a common early indicator of apoptosis.

Safety studies of PARP inhibitors have been extensively studied as a new class of anticancer agents. Each is an analogue of nicotinamide, and several potent and selective analogues have been reported thus far. Although PARP inhibitors have been studied over 30 years, the exact mechanism of their actions is still not fully understood. However, a general consensus appears to agree on two possible modes of their actions:

a. PARP-1 inhibitors interact with and inhibit PARP-1 by trapping the DNA-PARP-1 complexes-hence blocking the DNA repair activities (e.g. inhibition of PARylation) and causing radio/chemopotentiation.

b. Some PARP inhibitors may also trap PARP-1/2 DNA complex by way of an allosteric effect as shown by Murai [4,5,10,11].

Recent advancement and SAR of PARP inhibitors

The PARP-1 catalytic domain has been successfully crystallized without an exogenous ligand and co-crystallized with NAD+, which has facilitated the rational design of PARP-1 inhibitors. PARP-1 inhibitors serve as competitive catalytic inhibitors with NAD+, which block the auto-PARYlation post-DNA binding-an important step in successfully mounting a DNA repair response. The early knowledge and research on the basic pharmacophore nicotinamide, which is a weak PARP inhibitor, derived an overlay to design and develop next-generation PARP inhibitors (Figure 1) [11].

**Figure 1** : Required feature for PARP-1 inhibitor.

**Figure 2** : Clinically important PARP-1 inhibitors.
Iniparib (Figure 2), a PARP inhibitor developed against triple negative breast cancer, failed in phase III clinical trials [12]. In recent years, researchers have made an effort on designing a library of small molecule PARP inhibitors that offered improved potency to first generation drugs such as Iniparib. This helped pave the way for the next-generation of PARP inhibitors (Figure 2) [13]. From SAR studies of screened compounds against PARP, it was proposed and validated that restricting the degree of conformational freedom of the amide bond via formation of a bicycle or pseudo-ring system could enhance the PARP inhibitors performance and potency (Figure 1). To support this hypothesis several hetero cycles has been developed and all these molecules were found potent PARP inhibitors. This work has helped in the development of clinically relevant PARP inhibitors [14].

Griffin [19] designed and developed benzoazole carboxamides and imidazoles derivatives with Veliparib being the most potent compound of that series (Figure 1). Veliparib’s improved potency was attributed to the pseudo-intra molecular hydrogen bond between the imidazole nitrogen and the amide NH that restricted the degree of freedom of amide [15]. Ruf and co-workers rationally designed several PARP inhibitors based on the co-crystal structures of PARP inhibitors with the PARP-1 protein [16]. They concluded that hydrogen bonding between PARP-1 amino acid residues and amide core of PARP-1 inhibitors was a useful feature in the design of potent inhibitors [17]. Based upon these and other structure activity studies, key structural features have been identified in the design of potent PARP-1 inhibitors such as:

a. A conformationally restricted amide moiety attributed to pseudo-intra molecular hydrogen bonding, as stated above- (1 & 2 in Figure 1).

b. Bulky group decoration on the core scaffold improves drug potency represented by Olaparib and Rucaparib (3 in Figure 1).

c. Aryl group functionality (4 in Figure 1).

For some PARP-1 inhibitors, such as talazoparib, stereochimistry is important for activity. One of the talazoparib isomers was shown to exhibit 300 times improved potency over the other (Figure 2) [18,19].

FDA approval

FDA-approved PARP-1 inhibitors, such as Olaparib, Rucaparib, and Niraparib are successful drugs. Olaparib was produced by the Astra Zeneca as the first PARP-1 inhibitor for ovarian cancer. Olaparib was approved to be used as mono-therapy in ovarian cancer cases that have germline BRCA mutations. While not showing therapeutic potential against estrogen-positive breast cancer, it was approved for germline BRCA HER2-negative breast cancer and for patients that are tested with adjuvant, neoadjuvant. Another FDA-approved single-agent PARP inhibitor against ovarian cancer, Rucaparib, has been employed in patients that have either somatic or germline BRCA mutation and the patients that have gone through minimum of two chemotherapeutics regimes before that. Niraparib, an orally active PARP inhibitor, has been successfully approved in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer that have had either complete or partial response to platinum-based chemotherapy [20,21].

Conclusion and Future Prospective

For over three decades, medicinal chemists have focused on designing, characterizing, and validating PARP-1 inhibitors for their potency and activity against cancer. In addition, several groups have worked on comprehensively characterizing the mechanistic aspects of PARP activation and how inhibitors modulate their function. Current PARP-1 inhibitors on the market are non-selective and inhibit the function of both PARP-1 and PARP-2 proteins due to the oligomerization of PARP-1/2 and their high structural homology. Further efforts in characterizing their roles in DNA SSBR repair and the rational design of selective moieties will prove to be an effective method to develop more potent inhibitors. Additionally, studying the roles and biological implications of other PARP family proteins will open new drug discovery and therapeutic avenues.

References


